A Pilot/Feasibility Trial of 64Cu-DOTA-Daratumumab Positron Emission Tomography in Patients With Newly Diagnosed or Relapsed Multiple Myeloma
Latest Information Update: 15 Mar 2024
Price :
$35 *
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 07 Mar 2024 Status changed from active, no longer recruiting to completed.
- 06 Mar 2023 Planned End Date changed from 22 Jan 2023 to 22 Dec 2023.
- 22 Nov 2022 Planned End Date changed from 22 Jul 2022 to 22 Jan 2023.